Search
Propiolactone
go.drugbank.com/drugs/DB09348ApprovedWithdrawn[A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. Propiolactone was first commercially available in the United States in 1958.[A32144] … Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor.
Categories: Compounds used in a research, industrial, or household settingTrimethoprim
go.drugbank.com/drugs/DB00440ApprovedInvestigationalVet approvedTrimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it … [L11893,L11830] It is structurally and chemically related to [pyrimethamine], another antifolate antimicrobial used in the treatment of plasmodial infections.[T707]
Mixtures: SEPTRIN IV 5 ML 10 AMPUL, Sulfamethoxazole and Trimethoprim for Injection, USPSepetaprost
go.drugbank.com/drugs/DB12043InvestigationalSepetaprost has been used in trials studying the treatment of Open Angle-glaucoma, Ocular Hypertension, and Mild Open Angle-glaucoma (OAG).
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337Approved[L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025. … BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19.
Latamoxef
go.drugbank.com/drugs/DB04570ApprovedLatamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
go.drugbank.com/drugs/DB16709ApprovedStratagraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat) is an allogeneic cellularized scaffold product used for the treatment of adults with thermal burns containing … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound
Synonyms: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen, allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsatDasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39190] Severe hypoglycemia is an acute, life-threatening medical condition resulting from a profound drop in blood glucose levels. … [L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.
Categories: Glucagon Receptor AgonistsShark liver oil
go.drugbank.com/drugs/DB11088ApprovedShark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. … However the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species.
Flortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigational[A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. … It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114]
Categories: Compounds used in a research, industrial, or household settingMirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigational[L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with … [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.